

CERTIFICATE OF MAILING

I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage as first class mail under 37 C.F.R. 1.8 on the date indicated below and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

Date: September 8, 2004, 2004

Distribution

Attorney Docket No. 11000.1037c5
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Matthew SLEEMAN and J. Greg MURISON

Group Art Unit: 1614

Serial No.

10/613,413

Filed

July 3, 2003

For

FIBROBLAST GROWTH FACTOR RECEPTORS

AND METHODS FOR THEIR USE

Examiner

Ruixiang Li

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner For Patents P O Box 1450 Alexandria, VA 22313-1450

Dear Examiner:

The documents listed on the accompanying form PTO/SB/08 are cited in compliance with the provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98, as amended. Applicant does not concede that the references are "prior art" under 35 U.S.C. § 102 or 103, and specifically reserves the right to antedate such material, as by a showing under 37 C.F.R. § 1.131 or otherwise.

The attached PTO/SB/08 form identifies eight (8) listed references. Copies of each of the listed references are enclosed herewith for the Examiner's convenience.

This Supplemental Information Disclosure Statement is being filed prior to receipt of any substantive Office Action and therefore no fee or certification is required.

Respectfully submitted,

Janet Sleath

Registration No. 37,007

Date: September 8, 2004 SPECKMAN LAW GROUP PLLC

20601

PTO/SB/08 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substitute for form 1449A/PTO | Complete if Known | | |
|---|------------------------|-------------------------|--|
| | Application Number | 10/613,413 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | Filing Date | July 3, 2003 | |
| OTATE MENT BY ALL LIVE | First Named Inventor | Matthew Sleeman, et al. | |
| (use as many sheets as negessary) SEP 1 0 2004 | Art Unit | 1614 | |
| | Examiner Name | Ruixiang Li | |
| Sheet 1 of TARDEMARK | Attorney Docket Number | 11000.1037c5 | |

| U.S. PATENT DOCMENTS | | | | | |
|-----------------------|--------------|---|--------------------------------|--|--|
| Examiner Initials* | Cite No.1 | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | 1 | | | | |
| | 2 | | | | |
| | 3 | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|------|---|--------------------------------|---|--|----|
| Examiner Initials* | Cite | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear | |
| | | Country code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | T⁰ |
| | 1 | WO 99/6308 A | 12/09/1999 | Genetech, Inc. | | |
| | 2 | WO 01/09327 A | 02/08/2001 | Human Genome Sciences, Inc. | | |
| | 3 | WO 00/73454 A | 12/07/2000 | Genetech, Inc. | | |
| | 4 | WO 01/00673 A | 01/04/2001 | Millennium Pharm, Inc. | | |
| | 5 | WO 01/53312 | 07/26/2001 | Hyseq, Inc. | | |
| | 6 | WO 01/53455 A | 07/26/2001 | Hyseq, Inc. | | |
| | 7 | WO 01/60991 A | 08/23/2001 | Incyte Genomics, Inc. | | |
| | | | | | | |

| | OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | | |
|----------------------|---|--|----------------|--|--|
| Examiner Initials | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² | | |
| | 1 | SLEEMAN, M., ET AL., "Identification of a new 1-15, fibroblast growth factor receptor, FGFR5" 18-20 Gene, Elsevier Biomedical Press., Amsterdam, NL, June 2001, Vol. 271, No. 2, 27. | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| | i | 1 |
|-----------|----------------|---|
| Examiner | Date | |
| Signature | Considered | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEÉS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.